

The dates and times for the Medicare Listening Sessions are:

- Eliquis: Monday, October 30, 2023 at 12:00 – 1:30 PM EST
- Xarelto: Wednesday, November 15, 2023 at 2:00 – 3:30 PM EST

More details can be found at this link:

Medicare Drug Price Negotiation Program Patient-Focused Listening Sessions

<https://www.cms.gov/inflation-reduction-act-and-medicare/medicare-drug-price-negotiation-program-patient-focused-listening-sessions>

The deadline is now October 15 at 11:59 PM PDT (was October 2, which the page still reflects).

Here is where you register to speak

2023 Medicare Drug Price Negotiation Program Patient-Focused Listening Sessions: Speaker Registration

https://surveys.cms.gov/jfe/form/SV_e99r5VS1dDT6ege

CMS (Center for Medicare and Medicaid Services) expects a high level of interest in the Listening Sessions. CMS will use a process to randomly select speakers from among the individuals who register for the chance to speak. Approximately 20 speakers will be selected for each Listening Session. A confirmation email will be sent to selected speakers.

To accommodate as many speakers as possible during each session, public statements will be limited to no more than three minutes per person.


To help speakers in planning remarks, CMS is providing the following optional discussion topics:

- Patients' day-to-day experiences living with the condition(s) treated by the selected drug, including how the experience may differ for different patient populations as well as patient caregivers and families.
- How the selected drug impacts patients, including both benefits and side effects, as compared to the therapeutic alternative(s), and which outcomes matter most to patients with the condition(s) treated by the selected drug.
- Patient experiences of access, adherence, and affordability of the selected drug as compared to therapeutic alternative(s).
- Any other information about the selected drug, the condition(s) it is used to treat, and other treatments used for that condition(s) that the speaker believes is important.

See below for screenshots of the registration pages.


Below are screenshots of registration steps at https://surveys.cms.gov/jfe/form/SV_e99r5VS1dDT6ege

1. Acknowledgement: After entering yes, use right arrow to go to next page.- use right arrow at each step.



The screenshot shows the CMS logo at the top left. Below it is a paragraph of text: "I acknowledge that by completing this form I am consenting to any information I provide, including protected health information (PHI) and personally identifiable information (PII), being made public during the Listening Session through a live-stream broadcast and being posted publicly online following the Listening Session." Below the text are two radio button options: "Yes" (selected) and "No". At the bottom, there is a progress bar showing 0% completion, a left arrow button, and a right arrow button.

2. Contact info



The screenshot shows the CMS logo at the top left. Below it is the heading "Contact Information". There are four input fields: "First Name", "Last Name", "Email Address", and "Confirm Email Address". The "Email Address" field has a small yellow icon with a speech bubble and a question mark. At the bottom, there is a progress bar showing 0% completion and a right arrow button.

3. Are you representing an organization? You can represent yourself and make your own statement, but I'll be glad to share our data with you to share.



Please indicate if you are representing an organization or company in your public statement.

Yes

No

0%  100%

← →

4. Which session do you wish to speak at (best to choose the one for the anticoagulant you are taking)? Eliquis is first and Xarelto is last.



Please indicate which Listening Session you want to attend to provide a public statement. To register for the chance to provide a public statement at multiple Listening Sessions, you will need to complete this registration form once for each Listening Session.

Eliquis: Monday, October 30, 2023 at 12:00 – 1:30 PM ET

Enbrel: Tuesday, October 31, 2023 at 12:00 – 1:30 PM ET

Entresto: Wednesday, November 1, 2023 at 12:00 – 1:30 PM ET

Farxiga: Thursday, November 2, 2023 at 12:00 – 1:30 PM ET

Fiasp; Fiasp FlexTouch; Fiasp PenFill; NovoLog; NovoLog FlexPen; NovoLog PenFill: Friday, November 3, 2023 at 12:00 – 1:30 PM ET

Imbruvica: Monday, November 6, 2023 at 12:00 – 1:30 PM ET

Januvia: Tuesday, November 7, 2023 at 12:00 – 1:30 PM ET

Jardiance: Wednesday, November 8, 2023 at 12:00 – 1:30 PM ET

Stelara: Tuesday, November 14, 2023 at 12:00 – 1:30 PM ET

Xarelto: Wednesday, November 15, 2023 at 2:00 – 3:30 PM ET

5. Do you have conflicts of interest? Most likely, you don't, so choose No.



You are encouraged to share any financial conflicts of interest (COI) that could influence your remarks. Examples of financial COI include:

- A drug company or patient advocacy group pays for your travel or other expenses.
- A drug company gives you money in the form of a grant, contract, or consulting arrangement.
- You, your spouse, or an immediate family member is employed by a drug company.

If you do not want to share your financial interests, you may still register for the chance to speak at the Listening Session.

Do you have any financial COI that you wish to share?

Yes

No

Prefer not to answer

6. Choose Patient with experience with the selected drug.



Which of the following best describes the person completing this registration form?
(Select one)

A patient who has experience taking the selected drug or other treatment(s)

A caregiver for an individual who has experience taking the selected drug or other treatment(s)

A health care provider who has experience prescribing, dispensing, or administering the selected drug or its therapeutic alternative(s)

An academic researcher or other subject matter expert not affiliated with a manufacturer of the selected drug or its therapeutic alternative(s)

An academic researcher or other subject matter expert affiliated with a manufacturer of the selected drug or its therapeutic alternative(s)

A representative of a patient advocacy organization

Other

7. What do you wish to cover? Choose one or more.



Please indicate which discussion topics you wish to address in your public statement.
(Select all that apply)

Patients' day-to-day experiences living with the condition(s) treated by the selected drug, including how the experience may differ for different patient populations as well as patient caregivers and families.

How the selected drug impacts patients, including both benefits and side effects, and which outcomes matter most to patients with the condition treated by the selected drug.

Patient experiences of access, adherence, and affordability of current treatments.

Any other information about the selected drug, the condition(s) it is used to treat, and other treatments used for that condition(s) that the speaker believes is important. Please describe this other information in your answer to the next question.

0%  100%

8. Provide one or two sentences about your intended remarks. I included the screenshot of what I submitted.



Please provide one to two sentences about your intended remarks below, highlighting any key points that you wish to make. Please note that spoken remarks are limited to three minutes per person:

We have initiated a survey of the afib patient community about their experiences with rivaroxaban and other anticoagulants, including side effects and benefits, as well as access and affordability.

Characters remaining: 103

0%  100%

9. Will you provide real world data? If you wish to use facts that we collect from the patient community, then you can say yes.



Will you include real-world evidence or other real-world data in your spoken remarks? Real-world evidence is clinical evidence about the usage and potential health benefits or risks of a medical product derived from real-world data. Real-world data are data relating to patient health status and/or the delivery of health care routinely collected from a variety of sources.

Yes

No

← 0% — 100% →

10. Do you need translation? Obviously not. Press Complete Registration.



Do you require language translation or interpretation services?

Yes

No

← 0% — 100% **Complete Registration**

11. You'll get a confirmation like the one below that your submission is complete. While the ones I received said we'd be notified October 9, that has changed and the registration has been extended to October 15. We are not aware of the new expected notification date.



Thank you for registering for a chance to speak at a 2023 Medicare Drug Price Negotiation Program Patient-Focused Listening Session.

You will receive a confirmation email that you are registered.

Speakers will be randomly selected. Please watch your email the week of October 9, 2023 for notice of selection. You will have to confirm your ability to participate as well as any language translation or interpretation services needed.

In addition to the Listening Sessions, the public is invited to submit written input, if interested, in response to the 2023 CMS information collection request about selected drugs and evidence about alternative treatments. Submissions can include data on the selected drugs, therapeutic alternatives to the selected drugs, data related to unmet medical need and impacts on specific populations as well as the patient/caregiver experience. Information can be submitted [here](#) between September 1 - October 2, 2023.

You must register for each individual listening session at which you wish to have a chance to speak. Click [here](#) to fill out and submit another registration form.

0%  100%